---
title: "LP – FCSL Poster 2024: Flow Cytometry Processing and Analysis of Tumor Specimens: Testing Viability and Staining Post Shipping - TD2 Precision Oncology"
description: Dive into the frontline of innate immune function assessment with flow cytometry, focusing on phagocytosis and reactive oxygen species (ROS) measurement. Explore the intricate mechanisms of phagocytosis, a fundamental strategy employed by innate immune cells to combat pathogens. Delve into our innovative flow cytometry assays, revealing phagocytotic activity in various cell lines and respiratory burst in human monocytes and neutrophils. Uncover the potential applications of these assays in monitoring immune cell health in clinical trials, non-clinical studies, and drug screening endeavors. Join us as we advance towards whole blood assays and define cell populations for precise analysis, paving the way for comprehensive immune function assessment. Witness the versatility of these assays across species, offering valuable insights for translational medicine and drug development.Explore the robustness of flow cytometry processing and analysis for tumor specimens, even post-shipping, offering valuable insights for drug development. Uncover the rationale behind utilizing flow cytometry to analyze tumor models like EMT6, LL/2, and Pan02, crucial for understanding cancer progression and evaluating treatment efficacy. Delve into our methodology, demonstrating effective staining and viability assessment post-shipping, ensuring reliable flow cytometry results. Witness how tumor specimens maintain integrity and viability, retaining surface and intracellular marker integrity even after extended periods. Join us as we debunk reservations about shipping stability and advocate for the flexibility of specimen handling in drug development, emphasizing the importance of skilled analysis by qualified individuals. Elevate your research with flow cytometry, a cornerstone in advancing drug discovery and safety assessment.
image: https://td2inc.com/hubfs/Assets/Images/fcsl-poster-2024-7.png
---
×
[](https://td2inc.com/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
# Flow Cytometry Processing and Analysis of Tumor Specimens: Testing Viability and Staining Post Shipping
**Authors:** Christine Samuelson, Hillary Reif, Cabot Cornwall, Sarah Johnson, Rubina Pal, Khushbu Komal, Jayne Schaubhut, Jennifer J. Stewart, and Lynette Brown
Flow Contract Site Laboratory, 18323 Bothell Everett Hwy, Suite 110, Bothell, WA 98012
**Abstract:** Flow cytometry can be utilized to analyze a variety of tumor models that are commonly used for testing during the drug development process. EMT6, LL/2, and Pan02 are tumor models frequently used to study the development and progression of cancer, and test the effectiveness and potential side effects of new treatment options. Research done using these models provides valuable insight into the toxicology and safety of potential drug candidates. Due to reservations about shipping stability negatively affecting tumor’s viability and yield, researchers are often hesitant to use an offsite laboratory. However, a specialty laboratory may be the best choice for providing more detailed and comprehensive flow cytometry results for the specific analysis method.
### Download Now
## CONTACT US
## Get Started.
Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.
[Get Started Now](https://td2inc.com/contact-us/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
Office
13208 E. Shea Blvd,
Suite 100
Scottsdale, AZ 85259
Phone
(602) 358-8300
Connect with us
-
-
© 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)